These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37827216)

  • 1. Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
    Dos Santos L; Carbone F; Pacreau E; Diarra S; Luka M; Pigat N; Baures M; Navarro E; Anract J; Barry Delongchamps N; Cagnard N; Bost F; Nemazanyy I; Petitjean O; Hamaï A; Ménager M; Palea S; Guidotti JE; Goffin V
    Am J Pathol; 2024 Jan; 194(1):30-51. PubMed ID: 37827216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
    Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
    Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.
    Zhang R; Singh S; Pan C; Xu B; Kindblom J; Eng KH; Krolewski JJ; Nastiuk KL
    Am J Clin Exp Urol; 2023; 11(1):12-26. PubMed ID: 36923722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin.
    Kindblom J; Dillner K; Sahlin L; Robertson F; Ormandy C; Törnell J; Wennbo H
    Endocrinology; 2003 Jun; 144(6):2269-78. PubMed ID: 12746285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate.
    Dillner K; Kindblom J; Flores-Morales A; Shao R; Törnell J; Norstedt G; Wennbo H
    Endocrinology; 2003 Nov; 144(11):4955-66. PubMed ID: 12960074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced prostatic Esr1
    Sharkey C; Long X; Al-Faouri R; Strand D; Olumi AF; Wang Z
    J Pathol; 2024 Jul; 263(3):300-314. PubMed ID: 38606616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
    Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
    Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation.
    Jin BR; Kim HJ; Na JH; Lee WK; An HJ
    J Adv Res; 2024 Mar; 57():135-147. PubMed ID: 37061215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
    Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
    Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.
    Tong Y; Zhou RY
    Mediators Inflamm; 2020; 2020():7958316. PubMed ID: 33192175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
    Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
    Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
    Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
    J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant activated Notch1 promotes prostate enlargement driven by androgen signaling via disrupting mitochondrial function in mouse.
    Kang JW; He JP; Liu YN; Zhang Y; Song SS; Xu QX; Wei SW; Lu L; Meng XQ; Xu L; Guo B; Su RW
    Cell Mol Life Sci; 2024 Mar; 81(1):155. PubMed ID: 38538986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
    Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia.
    O'Malley KJ; Dhir R; Nelson JB; Bost J; Lin Y; Wang Z
    Prostate; 2009 Dec; 69(16):1716-23. PubMed ID: 19676094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating spatial transcriptomics and single-cell RNA-sequencing reveals the alterations in epithelial cells during nodular formation in benign prostatic hyperplasia.
    Fei X; Liu J; Xu J; Jing H; Cai Z; Yan J; Wu Z; Li H; Wang Z; Shen Y
    J Transl Med; 2024 Apr; 22(1):380. PubMed ID: 38654277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.